Core Viewpoint - The stock market activity has significantly increased since the beginning of the year, particularly in the Asia-Pacific region, marking a return of positive market sentiment after three years [1][3]. Group 1: Market Sentiment and Activity - Overall market sentiment has undergone a notable transformation since the beginning of the year, with expectations for active stock capital markets, merger and acquisition (M&A) markets, and bond capital markets from now until next year [3]. - The current market momentum is primarily driven by the technology sector, with industrial technology and medical technology identified as key focus areas, alongside signs of recovery in the financial services sector [3]. Group 2: Japan Market Insights - The Japanese market is currently experiencing heightened activity, with corporate reforms translating into increased M&A activity, and financial investment institutions actively seizing opportunities [3]. - There is a growing optimism regarding the Japanese market as reforms continue, despite the economy showing moderate growth, indicating clear signs of a turning point that has significantly improved market sentiment [3]. - A comprehensive recovery in transaction activities across major industries is anticipated from the second half of 2025 to 2026 [3].

Core Insights - The article highlights the importance of inclusive finance in supporting the growth of technology startups, particularly those that are asset-light and high-risk, which often struggle to secure traditional financing [1][2] - The case study of Tianjin's Small and Medium Enterprise Credit Financing Guarantee Co., Ltd. (Tianjin SME Guarantee) illustrates how innovative financing solutions can effectively address the funding challenges faced by tech startups [1][2] Group 1: Financing Solutions - Tianjin SME Guarantee's entrepreneurial guarantee business provides government-backed loans to support individual entrepreneurship and small businesses, aiming to alleviate financing difficulties [2][3] - The organization has developed a "bank supermarket" model, aggregating resources from over twenty banks to negotiate lower financing costs for startups [8][10] - The collaborative due diligence and parallel approval process with banks significantly reduces loan approval times, enhancing efficiency for startups [9][10] Group 2: Case Studies of Supported Companies - Lingzhi Haoyue Aviation Technology Co., Ltd. received 4 million yuan in credit support, resulting in a comprehensive loan rate of less than 2%, which is significantly lower than market rates [3][8] - Tianjin Tianrong Environmental Technology Co., Ltd. benefited from a 10 million yuan guarantee loan, with a minimal guarantee fee of 40,000 yuan, allowing for sustained investment in technology and market expansion [4][5][8] - Zhongke Xinchuan Medical Technology (Tianjin) Co., Ltd. secured 1 million yuan in funding to support its product launch, demonstrating the critical role of Tianjin SME Guarantee in facilitating market entry for new companies [5][11] Group 3: Innovative Risk Management - Tianjin SME Guarantee employs a "technology points system" to evaluate startups, reducing reliance on traditional financial metrics and enabling more companies to access financing [10][11] - The organization has implemented a "party-building credit enhancement" model, linking the effectiveness of a company's party-building work to its credit assessment, which has proven to enhance repayment reliability [10][11] Group 4: Comprehensive Support Services - Tianjin SME Guarantee offers services that extend beyond loan provision, supporting companies throughout their lifecycle from startup to growth and maturity phases [11][12] - The organization provides additional resources such as industry information and policy interpretation, positioning itself as a partner in the growth of tech companies [12][13] - As of July 2025, Tianjin SME Guarantee has provided 390 million yuan in entrepreneurial guarantee loans to 212 startups, demonstrating its significant impact on local economic development [12][13]

Core Viewpoint - The article emphasizes the significant advancement of Foundation Models (FM) in the potential applications of artificial intelligence (AI) in clinical care, highlighting the need for rigorous prospective validation and randomized controlled trials to bridge the gap between AI capabilities and real-world clinical environments [2][3][6]. Group 1: Foundation Model Development - A multi-modal visual-language ophthalmic foundation model named EyeFM was developed, which was validated through a prospective deployment across various global regions, including Asia, North America, Europe, and Africa [3][6]. - EyeFM was pre-trained using a diverse dataset of 14.5 million eye images, enabling it to perform various core clinical tasks effectively [6][11]. Group 2: Clinical Evaluation and Effectiveness - The effectiveness of EyeFM as a clinical assistance tool was evaluated through a randomized controlled trial involving 668 participants, showing a higher correct diagnosis rate of 92.2% compared to 75.4% in the control group [11][13]. - The study also indicated improved referral rates (92.2% vs 80.5%) and better self-management adherence (70.1% vs 49.1%) among the intervention group using EyeFM [11][13]. Group 3: Application and Future Implications - EyeFM serves as a comprehensive assistance system for ophthalmology, with potential applications across various clinical scenarios, enhancing the diagnostic capabilities of ophthalmologists and improving patient outcomes [12][13].

Group 1 - The project "Key Technologies and Application Research for Promoting Health in Children and Adolescents through Digital Intelligence" was launched to address issues like myopia, obesity, anxiety, and other health concerns among youth [1] - The project aims to utilize modern technologies such as artificial intelligence and big data to create a scientific, precise, and efficient health promotion system for children and adolescents [1] - The initiative is seen as a significant step in supporting national strategies and contributing to the Healthy China initiative, emphasizing multi-disciplinary collaboration for high-quality implementation [1] Group 2 - The project is led by the National Sports General Administration's Sports Science Research Institute, in collaboration with nine other institutions, including Peking University and Tsinghua University [2] - It focuses on developing wearable devices and health models tailored for children and adolescents, enhancing the capabilities of physical education teachers in promoting health through sports [1][2] - The project integrates resources from various fields such as sports science, computer science, public health, clinical medicine, and rehabilitation engineering to support the digital transformation of sports research [1]

Core Points - The document outlines the independent director system of Wuxi Xiangsheng Medical Technology Co., Ltd, emphasizing the importance of independent directors in corporate governance and their role in protecting the interests of minority shareholders [5][17][23] Group 1: Independent Director Responsibilities - Independent directors must perform their duties independently, free from influence by the company or its major shareholders [2][5] - They are required to participate in decision-making, supervision, and provide professional advice to safeguard the overall interests of the company and protect the legal rights of minority shareholders [2][17] - The board must include at least one-third independent directors, with a majority of independent directors on the audit committee [3][5] Group 2: Independence Requirements - Independent directors must not have any direct or indirect interests that could affect their independent judgment [5][6] - They can serve as independent directors for a maximum of three domestic listed companies to ensure they have sufficient time and energy to fulfill their responsibilities [3][5] Group 3: Nomination and Election Process - The board of directors and shareholders holding more than 1% of the company's shares can propose independent director candidates, who must be elected by the shareholders' meeting [8][10] - The nomination process requires thorough verification of the candidate's qualifications and independence [10][11] Group 4: Rights and Powers - Independent directors have the right to independently hire intermediaries for auditing, consulting, or verification of specific company matters [17][21] - They can propose the convening of temporary shareholders' meetings and board meetings [17][21] Group 5: Performance and Reporting - Independent directors must submit an annual performance report detailing their attendance at meetings and their involvement in various committees [36][37] - The company is required to provide necessary support and resources for independent directors to perform their duties effectively [37][38] Group 6: Compliance and Accountability - Independent directors must report to the stock exchange if they are dismissed or if there are obstacles to their ability to perform their duties [23][22] - The company is responsible for covering the costs incurred by independent directors when hiring professional institutions [42]

Meeting Overview - The second board meeting of Jianerkang Medical Technology Co., Ltd. was held on August 28, 2025, with all 9 directors present, complying with relevant laws and regulations [1][2]. Resolutions Passed - The board approved the full and summary reports for the 2025 semi-annual report, with a unanimous vote of 9 in favor [2]. - The board also approved the special report on the storage and use of raised funds for the first half of 2025, again with a unanimous vote of 9 in favor [2]. - A resolution was passed to change the company's registered capital, abolish the supervisory board, and amend the company's articles of association, with a unanimous vote of 9 in favor. This change aligns with the new Company Law effective from July 1, 2024 [3][4]. - The board approved the revision and formulation of several governance systems to enhance operational standards and governance structure, with a unanimous vote of 9 in favor [4]. - A proposal to convene the first extraordinary general meeting of shareholders in 2025 was also approved, with a unanimous vote of 9 in favor [5].

Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on September 16, 2025, at 14:30 [1] - The meeting will take place at the office building on the first floor, No. 1 Jiekang Road, Industrial Concentration Zone, Zhiqi Town, Jintan District, Changzhou City, Jiangsu Province [1] - Shareholders can vote through the Shanghai Stock Exchange's online voting system from 9:15 to 15:00 on the day of the meeting [1][2] Voting Procedures - The voting will be conducted through a combination of on-site and online voting methods [2] - Shareholders must register to attend the meeting and can authorize a representative to vote on their behalf [4] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts [3] Agenda Items - The meeting will review proposals that have been approved by the company's second board of directors [2] - Key proposals include changes to the company's registered capital and the cancellation of the supervisory board [2][8] Attendance Requirements - Shareholders must be registered by the close of trading on September 9, 2025, to attend the meeting [3] - Required documents for registration include proof of shareholding and identification [4] Contact Information - For inquiries, shareholders can contact the Securities Department at 0519-82446601 or via email at lp@chinajek.com [5]

Group 1 - The second meeting of the supervisory board of Jianerkang Medical Technology Co., Ltd. was held on August 28, 2025, with all three supervisors present, complying with relevant laws and regulations [1][2] - The supervisory board approved the 2025 semi-annual report, confirming that the report's preparation and review processes were legal and compliant, and accurately reflected the company's financial status and operational results [1][2] - The supervisory board also approved the special report on the use of raised funds for the first half of 2025, stating that the company adhered to legal procedures and that there were no significant risks associated with the use of these funds [2]

Group 1 - The company has established an Audit Committee under the Board of Directors to enhance decision-making and ensure effective supervision of the management team [1][4] - The Audit Committee consists of three directors, with at least two being independent directors, and is chaired by an independent director with accounting expertise [2][5] - The Audit Committee is responsible for reviewing financial information, supervising internal and external audits, and ensuring the establishment of effective internal controls [4][6] Group 2 - The Audit Committee must have a majority of its members present to exercise its powers, and it is required to hold at least one meeting each quarter [11][23] - The committee is tasked with evaluating the company's internal control systems and must report on its findings alongside the annual financial report [7][9] - The Audit Committee is also responsible for hiring and supervising external auditors, ensuring their independence and adherence to professional standards [10][13] Group 3 - The committee must disclose its annual performance and activities on the Shanghai Stock Exchange website alongside the company's annual report [4][6] - In case of any irregularities, the Audit Committee is obligated to prompt the Board to take necessary actions and disclose relevant information [7][10] - The committee's decisions require a majority vote from all members, and any conflicts of interest must be disclosed and managed appropriately [42][49]

| 公司代码：603716 | 塞力斯医疗科技集团股份有限公司2025 | 年半年度报告摘要 | | | --- | --- | --- | --- | | | 公司简称：塞力医疗 | | | | | 塞力斯医疗科技集团股份有限公司 | | | | | 塞力斯医疗科技集团股份有限公司2025 年半年度报告摘要 | | | | | 第一节 重要提示 | | | | 展规划，投资者应当到 | www.sse.com.cn 网站仔细阅读半年度报告全文。 | | | | 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | | | | | 无 | | | | | | 第二节 公司基本情况 | | | | | 公司股票简况 | | | | 股票种类 | 股票上市交易所 股票简称 | 股票代码 | 变更前股票 | | 简称 | | | | | A股 | 上海证券交易所 塞力医疗 | 603716 | 塞力斯 | | 联系人和联系方式 | 董事会秘书 | | 证券事务代表 | | 姓名 | 范莉 | 不适用 | | | 电话 | 027-83386020 | | | | 办公地址 | 武汉市东西湖 ...